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provided it is propeObjective: The impact of HIV-1 tropism on the emergence of non-AIDS events was
evaluated in a cohort of 116 antiretroviral therapy (ART) responder patients.
Methods: The patients were followed for the emergence of hypertension, renal impair-
ment, metabolic and bone disorders (defined as non-AIDS events) each 8 weeks at
standard visits. A V3 plasma sequence genotype analysis was performed at the time of
ART initiation and the geno2pheno algorithm with the results that defines the false-
positive rate (FPR) was used to infer HIV tropism. The associations between the non-
AIDS events and the FPR at baseline were evaluated using the x2 test for trend.
A Cox-regression analysis using the counting process formulation of Andersen and
Gill was performed to definewhether the emergence of non-AIDS events was correlated
to FPR.
Results: The prevalence of at least one non-AIDS event resulted higher in patients with
a FPR below 10% than in patients with a R5 virus (P¼0.033). Patients with a FPR below
5.0% most frequently developed non-AIDS events during ART (P¼0.01). A higher
prevalence of patients with at least two AIDS events was found in the group of patients
with a FPR below 5.0% with respect to the others (P<0.001). At multivariate
Cox-regression analysis, having an X4 virus and age were independently associated
with a higher probability of non-AIDS event development.
Conclusion: This study shows that an X4 virus, particularly a FPR less than 5%, is
related to non-AIDS events development. Further studies are warranted to understand
the mechanisms underlying this phenomenon.
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The introduction of antiretroviral therapy (ART) has
dramatically modified the natural course of HIV
infection, increasing life expectancy and consequently
the proportion of patients ageing with HIV [1]. Hence,stems Medicine, and bDepartment of Experiment
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rly cited. The work cannot be changed in any way oage-related complications currently represent one of the
most challenging concerns in addressing the management
of HIV-positive patients [2–4]. Cardiovascular disease,
hypertension, renal and liver pathologies and non-AIDS
malignancies are now collectively considered serious
non-AIDS events or diseases [5]. HIV-infected patientsal Medicine and Surgery, Tor Vergata University, Rome, Italy.
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732 AIDS 2016, Vol 30 No 5undergoing ART have been shown to be at increased risk
of developing non-AIDS events, compared with people
ageing without HIV infection [6–8].
In the context of an older HIV-infected population, a
deeper knowledge of the factors able to accelerate and
worsen ageing is warranted in order to improve both
quality of life and life expectancy.
The factors related to premature ageing in HIV-infected
patients are not fully understood, even if there is some
evidence of the pathogenetic role of the virus itself. HIV
directly affects the body along with chronic immune
activation and ART toxicity, which are responsible for
metabolic disorders, including diabetes mellitus, dyslipi-
demia and bone alterations, such as osteoporosis and
osteopenia [9,10].
The chemokine receptors CXCR4 (X4) and CCR5
(R5), used to enter target cells, play a pivotal role in HIV
transmission, pathogenesis and disease progression.
During the early phase of HIV-infection, R5-binding
viruses are more frequently involved, whereas later in the
course of the disease, viral variants expressing affinity for
the X4 co-receptor may be selected [11,12]. The
emergence of X4 variants has been shown to be
associated with a faster decline in the number of
peripheral blood CD4þ lymphocytes, more rapid
progression of the disease and a poorer prognosis for
survival [13–16]. Moreover, a significantly greater
decrease in CD4þ count and a higher number of clinical
events, such as AIDS-defining illnesses or death occurring
after ART initiation, were described among patients with
an X4 or dual mixed X4/R5 viral tropism, compared
with those harboring an R5-binding variant [17].
Although there are data that demonstrate how latent viral
diversity characteristics are unlikely to be a major driver of
persistent HIV-associated immune activation and ageing
[18,19], until today, there have been no clinical studies
that directly correlate the HIV-1 tropism isolate at the
beginning of ART with the onset of non-AIDS events
during treatment.
This study aimed to evaluate the impact of HIV-1 tropism
on the emergence of non-AIDS events after ART
initiation in a cohort of 116 patients as their first-line
regimen and as full responders to ART.Methods
One hundred and sixteen HIV-1 drug-naive infected
patients attending the Clinic of Infectious Disease of Tor
Vergata University of Rome, Italy, were enrolled in the
study. All patients began first-line antiretroviral treatment
between 2008 and 2013, and a V3 plasma sequence wasavailable at the time of ART initiation for each patient. All
patients received an effective ART (viral load <50/ml)
and were considered for the emergence of at least one
non-AIDS event during the follow-up period of their
first antiretroviral treatment. To avoid any influence of
active viral replication on the emergence of non-AIDS
events, we enrolled only patients fully responder to ART.
The following diseases were considered non-AIDS
events: hypertension (systolic blood pressure
140mmHg or diastolic blood pressure 90 mmHg,
or both, on repeated examination), metabolic disorder
(high blood sugar level, excess body fat around the waist,
abnormal blood cholesterol and triglyceride levels), bone
disorders [osteopenia, considered as a T-score of –1 to –
2.5 standard deviations with dual-energy x-ray absorp-
tiometry (DXA), osteoporosis, considered as a T-score of
less than –2.5 SD], renal impairment (confirmed
glomerular filtration rate decline of >25% from baseline
and to a level<60ml/min per 1.73 m2, and/or a repeated
proteinuria >200mg/day). All patients were evaluated
each 8 weeks for hypertension, metabolic disorder and
renal impairment. DXA evaluation was performed for
each patient every 12 months. No patients developed
cancer or myocardial infarction during the observation
period therefore the analysis was limited to the above
reported non-AIDS events. Data were extracted from a
database specifically created for the collection of clinical
and laboratory follow-up data of patients for the entire
period of clinical observation. In particular, demographic
data, risk factors for HIVacquisition, Center for Diseases
Control (CDC) staging (revised 1993), blood bio-
chemical parameters, CD4þ cell count, HIV tropism
isolate characteristics were evaluated before the beginning
of ART and plasma viral load, clinical and therapeutic
history and timing of non-AIDS events were evaluated
after the beginning of ART.
No specific ethics committee’s consent was required due
to the retrospective characteristic of the study based on
information available from existing clinical documen-
tation [Determination of the Italian Agency of Drug
(AIFA) of 20March 2008].With respect to the privacy, all
personal information was treated in a confidential manner
and all clinical data were analyzed anonymously.
Determination of HIV-1 genotypic tropism
testing
V3 genotype analyses were performed as previously
described [20]. Briefly, HIV-1 co-receptor usage was
inferred from the V3 nucleotide sequences by using the
geno2pheno algorithm, set at false-positive rate (FPR) of
10%, as recommended by current guidelines [21,22],
available at the following website: http://coreceptor.-
bioinf.mpi-sb.mpg.de/cgi-bin/coreceptor.pl. The sys-
tem uses a support vector machine trained with a set
of genotypic sequences with corresponding R5 or DM/
X4 phenotypes. The tool is based on nucleotide
HIV-tropism and non-AIDS events Maffongelli et al. 733sequences and therefore also analyses subsequent amino-
acid mixtures. The result of the interpretation is given as a
quantitative value, the FPR that defines the probability of
classifying an R5-virus falsely as X4.
To evaluate the impact of the burden of HIV-1 CXCR4-
using species on the number and type of non-AIDS-
related events, FPR values were further stratified
according to the following five FPR (%) ranges: for
X4 viruses, not more than five and 5–10; for R5 viruses,
10–20, 20–60, and above 60 [23,24]. In this categor-
ization, all five ranges are left-open and right-closed (e.g.
5; >5 and 10; >10 and 20; >20 and 60; and
>60).
Statistical analysis
Potential associations between the number and type of
non-AIDS events that occurred during first-line ART
and the FPR of V3 sequence at baseline were evaluated
using the x2 test for trend (P <0.05), after stratifying the
FPR for the five categories mentioned above. Moreover,
a x2 test was used to compare categorical variables in
patients infected with viruses characterized by a FPR
below 5% and 5–10% vs. patients infected with viruses
characterized by a FPR above 60%. Associations between
continuous variables, such as viral load, CD4þ cell count,
age, year of diagnosis, and HIV-1 tropism, were evaluated
using the Mann–Whitney test.
A uni- and multivariate Cox-regression analysis using the
counting process formulation of Andersen and Gill was
also performed to define whether the emergence of non-
AIDS events during treatment was correlated to the
baseline presence of an X4 virus (setting the FPR at 10%)
and whether this association increased by decreasing the
FPR. The following variables were considered for this
analysis: patient’s demographics, year of diagnosis, HIV-1
subtype defined on pol sequences, zenith viremia and
nadir CD4þ cell count, CD4þ cell count at non-AIDS
event diagnosis, years under treatment, presence of
virological blips (defined as viral load detection 50 and
<1000 copies/ml), number of visits per year of ART, and
first-line antiretroviral composition.Results
Patients’ characteristics
The characteristics of the study population at the time of
comorbidities diagnosis are shown in Table 1. Among the
116 included patients, the majority were male (66.4%),
with a median age of 45 years, heterosexual orientation
and infection by HIV-1 subtype B. Only one-third of the
patients were in an advanced phase (class CDC C) of
infection. All patients began first-line ART and were
treated for a median time of 3 years. The prevalent ART
regimens included the FTCþTDF (emtricitabine þtenofovir) combined with a protease inhibitor or non-
nucleoside reverse transcriptase inhibitor (NNRTI)
(56 and 25%, respectively), followed by ABCþ3TC
(abacavir þ lamivudine) combined with a protease
inhibitor (11.2%).
Virological success was reached in a median time of 16
weeks (range 8–48 weeks), and all patients maintained
virological suppression during the entire observation
period [median (interquartile, IQR): 3.0 years (2.0–4.0)].
Virological blips (defined as a viral load of 50 and
<1000 copies/ml, preceded and followed by undetect-
able values) were observed in 19.8% of patients.
During a follow-up period under effective ART, overall,
72 patients (62.1%) developed non-AIDS events: 44
patients developed one event, while 28 patients
experienced more than one non-AIDS event. Among
the 116 patients studied, hypertension and metabolic
disorders were observed in 20 and 31 patients,
respectively, kidney diseases in 37 patients, and osteo-
porosis in 25 patients.
By evaluating the genotypic tropism at baseline of the first
antiretroviral regimen by geno2pheno algorithm set at
10%, we found that 32 out of 116 (27.6%) patients carried
an X4 tropic virus, and 84 (72.4%) carried an R5 tropic
virus. By further stratifying patients for the five FPR (%)
ranges, 17 (14.6%) carried an X4 virus with a FPR below
5%, 15 (12.9%) carried an X4 virus with a FPR 5–10%,
12 (10.3%) carried an R5 virus with a FPR 10–20%, 37
(33.9%) carried an R5 virus with a FPR 20–60%, and
35 (30.2%) carried an R5 virus with a FPR above 60%
(Table 1).
Patient characteristics according to
false-positive rate
Characteristics of patients according to the five FPR (%)
ranges are reported in Table 1. Patients infected by an X4
tropic virus (setting the FPR at 10%) have a significantly
lower number of CD4þ cell counts at nadir, compared
with patients infected by an R5 virus [nadir CD4þ cell
count: 90 (23–174) vs. 181 (73–330), P¼ 0.001].
Moreover, patients infected by an X4 virus with a
FPR below 5% have a significantly lower number of
CD4þ cell counts at the first non-AIDS event develop-
ment, compared with patients infected by an X4 virus
with a FPR 5–10 and to patients infected by an R5 virus
with a FPR 10–20, 20–60, or above 60 (CD4þ cell count
at first comorbidity diagnosis: P¼ 0.054).
In contrast, no correlations were found between FPR
ranges and viral load at the zenith point (P¼ 0.832).
Furthermore, no differences were observed between
patients with a different HIV tropism isolate with respect
to age, year of diagnosis, ART length, ART combination
and presence of virological blips during virological
suppression.
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HIV-tropism and non-AIDS events Maffongelli et al. 735Association between false-positive rate and
non-AIDS events
By analyzing the correlation between the FPR and
evidence of non-AIDS events during the first-line ART
treatment, we found that the prevalence of at least one
non-AIDS event was higher in patients infected by an X4
virus (FPR set at 10%) than in patients infected by an R5
virus [25 (78.1%) vs. 47 (56.0%), relative risk¼ 1.40
(95%confidence interval, CI 1.00–1.74), P¼ 0.033].
This prevalence also increased by decreasing the FPR
(Fig. 1a). In particular, patients infected by an X4 virus
with a FPR less than 5% most frequently developed non-
AIDS events during ART than patients infected by an R5
virus with a FPR over 60% [15 (88.2%) vs. 18 (51.4%),
relative risk: 1.72 (95%CI 1.08–2.09), P¼ 0.01] (Fig. 1a).
Moreover, patients with lower FPR (<5% and 5–10%)
were more prone to develop more than one non-AIDS
event with respect to patients infected by anR5 virus with
a FPR over 60% [9 (52.9%) for FPR<5.0% and 8 (53.3%)
for FPR 5–10 vs. 3 (8.6%) for FPR >60, relative risk:0
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Fig. 1. Prevalence of patients with evidence of non-AIDS events s
events. (a) Significant correlation between having FPR below 5.0%
event. (b) Significant correlation between having FPR below 5.0%
number of patients for those the non-AIDS event was diagnosed wa
the x2 test for trend. FPR, false-positive rate.6.18 (95%CI 1.80–26.41) and 6.22 (95%CI 1.76–26.77),
respectively, P< 0.001 each one] (Fig. 1a).
Interestingly, by analyzing the correlation between HIV-1
tropism and each specific non-AIDS event, dysmetabolic
syndrome and hypertension events increased by decreas-
ing the FPR, and their emergence was more frequently
observed in patients infected by an X4 virus with a FPR
less than 5.0% than in patients infected by an R5 virus
with a FPR above 60% [dysmetabolic syndrome: 11
(64.7%) vs. 4 (11.4%), relative risk: 5.6 (95%CI 2.02–
17.69), P< 0.001; hypertension: 8 (47.1%) vs. 0 (0.0%),
relative risk: inf.(95%CI 3.57–inf.), P< 0.001) (Fig. 1b).
In the multivariate Cox-regression analysis based on
the counting process formulation of Andersen and Gill
(Table 2), the presence of an X4 virus at treatment
baseline was an independent factor significantly corre-
lated with a higher probability of non-AIDS events
development during ART [adjusted hazard risk: 1.69atients with at least two
comorbidities
FPR < 5
FPR 5−10
FPR 10−20
FPR 20−60
FPR > 60
P < 0.001
FPR (%)
9 8
3
5
3
tients with
metabolic
yndrome
Patients with
hypertension
FPR < 5
FPR 5−10
FPR 10−20
FPR 20−60
FPR > 60
 < 0.001 P < 0.001
FPR (%)
6
2 8
4
8
5 4
3
0
tratified for FPR at baseline and number or type of non-AIDS
and the emergence of at least one or more than one non-AIDS
and the emergence of each non-AIDS event. The absolute
s reported upper each column. P values were calculated using
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HIV-tropism and non-AIDS events Maffongelli et al. 737(95%CI 1.19–2.39), P¼ 0.003]. By stratifying for FPR,
X4 viruses with both FPR less than 5% and 5–10% were
independent factors significantly correlated with a higher
probability of non-AIDS events development during
first-line ART, compared with R5 viruses with FPR
above 60% [adjusted hazard risk: 1.89 (95%CI 1.17–3.04)
and 2.02 (95%CI 1.23–3.31) P¼ 0.012]. Another factor
independently correlated to the development of non-
AIDS events was age [per 1 year increase, adjusted hazard
risk: 1.03 (95%CI 1.02–1.05), P< 0.001]. Interestingly,
CD4þ cell count at nadir and at the time of non-AIDS
event diagnosis were not significantly correlated with
non-AIDS-event development; nevertheless, there was a
correlation between low CD4þ cell count at nadir and an
X4 virus.
Due to the strong association between the presence of an
X4 virus at ART initiation and the emergence of
hypertension and/or metabolic syndrome, we performed
a multivariate Cox-regression analysis taking into account
only these two non-AIDS events (Table 3). In this analysis,
the presence of an X4 virus at treatment baseline was
confirmed to be an independent factor significantly
correlated with a higher probability of hypertension
and/or metabolic syndrome development during ART
[adjusted hazard risk: 2.29 (95%CI1.39–3.76),P¼ 0.001],
also when stratified for FPR [adjusted hazard risk: 3.58
(95%CI 1.41–9.10) for FPR <5.0% and 4.86 (95%CI
2.00–11.82) for FPR 5–10, P< 0.001). Interestingly, also
R5 viruses characterized by FPR 10–20% positively
correlated to the development of hypertension and/or
metabolic syndrome [adjusted hazard risk: 2.87 (95%CI
1.02–8.11)], suggesting that not only X4 viruses but also
theR5ones characterizedbyFPRbelow20%canbe at risk
for the development of these specific non-AIDS events.Discussion
The results of this study demonstrate that patients infected
by an X4 virus were more prone than those infected by
R5 viruses to develop non-AIDS events during first-line
ART and that this correlation is intensified when low
FPRs were considered.
An X4 tropism was already widely associated with a faster
decline in the number of peripheral blood CD4þ
lymphocytes, a more rapid progression of the infection
and poorer survival [13–15]. A significantly higher
number of AIDS-defining illnesses or death after ART
initiation has also been observed among patients
harboring an X4 virus, compared with those infected
by an R5 virus [17]. Previous findings also suggested that
X4 viruses, characterized by a low geno2pheno FPR,
caused poorer immunological reconstitution and lower
virological response in HIV-1-infected patients starting
first-line therapy, with respect to R5 viruses with high
FPR [23,24]. Here, we provided evidence that anX4 virus can also be predictive for the development of
non-AIDS events.
The reasons for the rapid clinical evolution characterizing
patients infected by an X4 HIV strain are not fully
understood. Recently, Saracino et al. demonstrated a
relationship between X4 tropism and the presence of
surrogate markers of infection, such as high-sensitivity
PCR, D-dimer, interleukin 6, interleukin 7 [18].
However, no correlation was found between the co-
receptor tropism of latent virus and markers of immune
activation [19], suggesting that other factors drive
immune activation that persists despite effective treat-
ment. Previous studies showed that naı¨ve CD4þ T cells
expressed the CXCR4 receptor more frequently than
others, suggesting that these cells represented the largest
pool of CD4þ T cells depleted after a HIV-1 X4 virus
infection [25]. This finding can explain why X4 tropic
HIV isolates contribute to the decrease in T-cell numbers
[26]. In line with these findings, expression of the
CXCR4 co-receptor on T cells has been found to be
increased, compared with the expression of CCR5
among elderly donors, suggesting a specific enhancement
of CXCR4 expression with age [27] that could facilitate
replication of strains with a low FPR and acceleration of
HIV progression in older people.
In a recent paper, Lapadula and coworkers [28]
demonstrated as ART-treated patients failing to restore
CD4þ to more than 200 cells/ml run a greater risk of
serious non-AIDS events and how this correlates with
progression to AIDS. Previously it had been suggested
that lowCD4þ/CD8þ ratiowas associated with increased
risk of serious events and deaths [29]. Nevertheless, in
both the papers, a correlation between CD4þ cell
recovery or CD4þ/CD8þ ratio during ART and HIV
tropism is missing. In our study population, the presence
of an X4-tropism isolate at the beginning of treatment
was significant associated with lower nadir of CD4þ
count, in univariate analysis, and at a lower CD4þ cell
number at the first non-AIDS-event development. This
datum should suggest that an X4 tropic virus is related
with a major loss and a limited recovery of CD4þ cells and
allows to argue that the immunological damage secondary
to X4-tropism strains could be difficult to be recovered
also after years of effective ART. Probably the small
number of our population did not allow us to obtain a
more reliable result.
Our data also confirmed the already-known association
between the development of non-AIDS events and
increased age. As suggested by several papers, this
association can be explained by the development of
mitochondrial dysfunction, the consequent poor
response to oxidative stress, telomerase inhibition and
the telomere shortening associated with biological
senescence in HIV-positive people [30–38]. There is
an abundance of evidence that oxidative stress, following
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HIV-tropism and non-AIDS events Maffongelli et al. 739the accumulation of free radicals, and mitochondrial
dysfunction has a major part in the development of
chronic and degenerative illnesses such as cancer,
autoimmune disorders, ageing, cataracts, rheumatoid
arthritis, cardiovascular and neurodegenerative diseases in
HIV-negative people [39–43].
ART drugs have been implicated in the pathogenesis of
renal damage, redistribution of body fat, bone remodel-
ing, insulin resistance, diabetes, dyslipidemia and
cardiovascular disease [44–46]. Nucleoside reverse
transcriptase inhibitor use has been historically implicated
in mitochondrial damage and telomerase inhibition [47].
The limited size of our study population did not allow to
obtain any correlation between the use of specific ART
regimen composition and the emergence of defined
non-AIDS events.
In HIV-positive patients, a severe immune-deficiency
condition and intermittent viremia were identified as risk
factors for the development of certain age-related
comorbidities [48–51]. Additionally, cumulative viral
load exposure (defined as viremia copy-years) in treated
patients has been shown to be associated with the risk of
clinical events and mortality [52,53]. In our work, neither
viral blips nor the zenith of HIV viremia values seems to
correlate with the development of non-AIDS events,
whereas, patients with more advanced HIV disease (stage
CDC C) in the multivariate analysis appear to have a
higher correlation with the occurrence of non-AIDS
events (P< 0.044) (Table 2).
In contrast to the studies of other authors [54,55], in this
study, no correlation was found between having a lower
FPR and older age, demonstrating that X4 tropism has per
se a direct effect on non-AIDS-event development.
Before drawing conclusions, a few limitations of our
study need to be discussed. The pathogenesis of
comorbidities such as hypertension and dysmetabolic
syndrome is certainly multifactorial and involves genetic
predisposition and environmental factors. This infor-
mation is not always present in the medical records of our
patient population; thus, the collection of such data was
partial and insufficient to exclude a correlation with
hereditary factors or lifestyle. The evaluation of viral
tropism through the V3 nucleotide sequence study was
performed on plasma virus before the beginning of
treatment, and no other evaluation was performed on
archived virus on the few occasions of viral blips during
treatment; thus, we have not explored the possibility of
viral tropism modification in the course of treatment.
However, a tropism switch in treated patients with
undetectable plasma viremia is improbable [56,57].
In conclusion, our findings show that an X4 virus and
particularly a FPR below 5% defines patients at high risk
of non-AIDS-events development, even in the setting offull suppressive antiretroviral treatment. Nevertheless,
further studies on larger and more homogeneous cohorts
are warranted to strengthen these results and to explore
the possible pathogenetic mechanisms at the base of
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